IL124236A - Pharmaceutical composition for treating or reversing diabetic cardiomyopathy comprising aldose reductase inhibitor - Google Patents

Pharmaceutical composition for treating or reversing diabetic cardiomyopathy comprising aldose reductase inhibitor

Info

Publication number
IL124236A
IL124236A IL12423698A IL12423698A IL124236A IL 124236 A IL124236 A IL 124236A IL 12423698 A IL12423698 A IL 12423698A IL 12423698 A IL12423698 A IL 12423698A IL 124236 A IL124236 A IL 124236A
Authority
IL
Israel
Prior art keywords
treating
pharmaceutical composition
aldose reductase
reductase inhibitor
diabetic cardiomyopathy
Prior art date
Application number
IL12423698A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL124236A publication Critical patent/IL124236A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL12423698A 1997-05-05 1998-04-27 Pharmaceutical composition for treating or reversing diabetic cardiomyopathy comprising aldose reductase inhibitor IL124236A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4582297P 1997-05-05 1997-05-05

Publications (1)

Publication Number Publication Date
IL124236A true IL124236A (en) 2003-01-12

Family

ID=21940071

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12423698A IL124236A (en) 1997-05-05 1998-04-27 Pharmaceutical composition for treating or reversing diabetic cardiomyopathy comprising aldose reductase inhibitor

Country Status (17)

Country Link
US (1) US5990111A (fr)
EP (1) EP0880964B1 (fr)
JP (1) JP3010153B2 (fr)
KR (1) KR19980086748A (fr)
AT (1) ATE277607T1 (fr)
AU (1) AU725621B2 (fr)
CA (1) CA2236553C (fr)
DE (1) DE69826561T2 (fr)
DK (1) DK0880964T3 (fr)
ES (1) ES2227773T3 (fr)
HU (1) HUP9801022A3 (fr)
IL (1) IL124236A (fr)
MY (1) MY136261A (fr)
NZ (1) NZ330359A (fr)
PT (1) PT880964E (fr)
TW (1) TW589184B (fr)
ZA (1) ZA983720B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413965B1 (en) * 1999-06-30 2002-07-02 Pfizer Inc. Compositions and treatment for diabetic complications
US6555540B1 (en) * 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
US6426341B1 (en) * 1999-06-30 2002-07-30 Pfizer Inc. Treatment for diabetic complications
AU7063300A (en) * 1999-08-23 2001-03-19 University Of Virginia Patent Foundation Method and apparatus for predicting the risk of hypoglycemia
US20020068740A1 (en) * 1999-12-07 2002-06-06 Mylari Banavara L. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
US6380200B1 (en) * 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
CN1526023B (zh) * 2001-03-30 2012-09-05 香港中文大学 针对醛糖还原酶基因的引物和探针在制备用于确定白内障风险的组合物中的应用
WO2003105864A1 (fr) * 2002-06-13 2003-12-24 Board Of Regents, The University Of Texas System Methodes et compositions impliquant des inhibiteurs de l'aldose reductase
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
CA2685202C (fr) 2007-03-23 2017-11-28 The Board Of Regents Of The University Of Texas System Methodes de traitement de l'asthme allergique
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
AU2011348074B2 (en) 2010-12-23 2016-04-28 The Board Of Regents Of The University Of Texas System Methods for treating COPD

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL80475A (en) * 1985-11-07 1993-01-31 Pfizer Heterocyclic-substituted 4-oxo (or thio)-3h- phthalazinyl-acetic acid derivatives and pharmaceutical compositions containing them
US4748280A (en) * 1985-11-07 1988-05-31 Pfizer Inc. Certain chlorination process for preparing 2-chloro-1,1,1-(C1 -C6)
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4743611A (en) * 1986-07-02 1988-05-10 American Home Products Corp. Naphthalenylsulfonylimidazolidinediones and their thioxo analogs useful as aldose reductase inhibitors
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
EP0322153A3 (fr) * 1987-12-21 1990-08-16 Pfizer Inc. Acides hétérocyclyl oxophtalazinyl acétiques
US4954629A (en) * 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
US5164391A (en) * 1989-09-20 1992-11-17 Sanwa Kagaku Kenkyusho Co., Ltd. Hydantoin derivatives for treating complications of diabetes and circulatory diseases
FI922308L (fi) * 1989-12-15 1992-05-21 Pfizer Substituerade oxoftalazinylaettiks- syror och deras analoger.
US5064830A (en) * 1990-08-02 1991-11-12 Pfizer Inc. Lowering of blood uric acid levels
WO1994007867A1 (fr) * 1992-09-28 1994-04-14 Pfizer Inc. Pyrimidines substituees pour le controle des complications diabetiques
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
US5834466A (en) * 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia

Also Published As

Publication number Publication date
DK0880964T3 (da) 2004-12-27
NZ330359A (en) 2000-06-23
EP0880964A3 (fr) 2002-07-17
HUP9801022A3 (en) 2001-10-29
KR19980086748A (ko) 1998-12-05
PT880964E (pt) 2004-12-31
ZA983720B (en) 1999-11-04
EP0880964B1 (fr) 2004-09-29
AU725621B2 (en) 2000-10-19
ES2227773T3 (es) 2005-04-01
DE69826561D1 (de) 2004-11-04
JP3010153B2 (ja) 2000-02-14
EP0880964A2 (fr) 1998-12-02
US5990111A (en) 1999-11-23
TW589184B (en) 2004-06-01
CA2236553C (fr) 2002-10-29
MY136261A (en) 2008-09-30
DE69826561T2 (de) 2006-03-09
ATE277607T1 (de) 2004-10-15
HUP9801022A2 (hu) 2000-03-28
AU6380198A (en) 1998-11-05
JPH10316588A (ja) 1998-12-02
CA2236553A1 (fr) 1998-11-05

Similar Documents

Publication Publication Date Title
WO2003053383A3 (fr) Utilisation cosmetique d’au moins une hydrophobine pour le traitement des matieres keratiniques
PT1479385E (pt) Utilização de inibidores de ciclo-oxigenase 2 no tratamento e na prevenção de neoplasias
EE04356B1 (et) aP2 inhibiitor kasutamiseks suhkurtõve ravis ja seda sisaldav ravimkoostis
DE60210093D1 (de) Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und -tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes
MXPA03003870A (es) Terapia de combinacion que comprende agentes antidiabeticos y anticonvulsionantes.
TR199802441A3 (tr) Kanda asiri ürik asit bulunmasinin tedavisi ve önlenmesi için yöntem ve terkip.
EP0909561A3 (fr) Utilisation de la réboxétine pour le traitement du trouble de déficit de l'attention/hyperactivité
ZA983720B (en) Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy.
EP0930067A3 (fr) Inhibiteurs de mmp dans le traitement de l'angiogenese oculaire
EE200300213A (et) SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks
AU8851298A (en) L-threonate ferrous, as well as pharmaceutical composition and use for improvingand treating human anemia thereof
EP1251847A4 (fr) Nouvel emploi de la prodigiosine pour traiter le diabete
IL139144A0 (en) Mycobacterial inhibitors
IL130500A (en) Use of comt inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions
AU2002257598A1 (en) Agent for treating diabetes mellitus
IL126651A (en) Acyl urea compounds for the treatment of coccidioidomycosis in warm-blooded animals
ZA200209835B (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or anti-metabolites.
MY140504A (en) Statin-mmp inhibitor combinations
WO2002005796A3 (fr) Methode de traitement de l'infection
AUPR916101A0 (en) Method of treating halitosis
ZA982808B (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia
WO2003004631A3 (fr) Utilisation d'inhibiteurs de l'expression ou de l'activite de p8/com1 pour le traitement des tumeurs
ID21653A (id) Komposisi untuk pengobatan atau pencegahan pankreatitis yang mengandung turunan diarilalkana sebagai bahan aktif
FR2786099B1 (fr) Nouvelle application therapeutique de la 1,6-dimethyl-8beta- hydroxymethyl-10alpha-methoxyergoline
NZ523676A (en) Use of cetyl myristate and cetyl palmitate to treat irritable bowel syndrome or irritable bowel disease

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees